tracken
Gilead Sciences Aktie News
Positiv
Reuters
●
14 Tage alt
Gilead Sciences said on Wednesday it has started work on a new pharmaceutical development and manufacturing hub at its headquarters in Foster City, California, as part of its planned $32 billion investment in domestic manufacturing.
Neutral
Business Wire
●
14 Tage alt
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences (Nasdaq: GILD) today celebrates the groundbreaking of its new Pharmaceutical Development and Manufacturing (PDM) Technical Development Center (NTDC) at the company's Foster City headquarters. This milestone marks continued momentum in Gilead's multi-year strategy to drive growth and scientific leadership across virology, oncology, and inflam...
Positiv
Seeking Alpha
●
15 Tage alt
Despite retail investors' cautious attitude toward Gilead Sciences, it once again beat analysts' expectations by a wide margin. In my estimation, Gilead's main star remains Biktarvy, which leaves competitors in the HIV-1 therapeutics market far behind, demonstrating record sales figures. In addition, the launch of Livdelzi and lenacapavir was extremely successful, which offsets the weak perform...
Positiv
Reuters
●
22 Tage alt
The European Commission has granted marketing authorization for Gilead Sciences' twice-yearly injection for preventing HIV infection, the company said on Tuesday.
Positiv
Investors Business Daily
●
22 Tage alt
Gilead Sciences won European approval Tuesday for its new twice-annual HIV prevention shot, now called Yeytuo.
Neutral
Business Wire
●
22 Tage alt
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Yeytuo® (lenacapavir)—the company's twice-yearly injectable HIV-1 capsid inhibitor—for use as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents with increased HIV-1 acquisition r...
Positiv
Reuters
●
27 Tage alt
Gilead Sciences' unit Kite Pharma said on Thursday it will acquire privately-held biotech firm Interius BioTherapeutics for $350 million in cash to advance CAR T-cell cancer therapies that are delivered directly into patients.
Negativ
Investors Business Daily
●
27 Tage alt
Gilead stock toppled Thursday on a report CVS won't add the company's new HIV prevention drug, Yeztugo, to its commercial plans for now.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
